STOCK TITAN

QuidelOrtho Corporation (QDEL) Stock News, Feb-May 2024

QDEL NASDAQ

QuidelOrtho Corporation reports developments in in vitro diagnostics, including rapid testing, immunoassay and molecular testing, clinical chemistry, transfusion medicine and point-of-care diagnostic platforms. Company updates commonly address financial results, revenue trends, guidance, respiratory testing seasonality, international market conditions and portfolio activity across labs, cardiac, immunohematology and molecular diagnostics.

Recurring news also covers product and technology developments such as the LEX VELO System, a point-of-care molecular PCR platform with FDA 510(k) clearance and CLIA waived status for Flu A, Flu B and COVID-19 testing, as well as diagnostic education topics including syphilis screening and high-sensitivity troponin. Governance and management changes appear alongside business updates and investor conference participation.

Rhea-AI Summary

QuidelOrtho (Nasdaq: QDEL) has launched a new state-of-the-art distribution center in Pedricktown, New Jersey, enhancing its U.S. distribution footprint. This strategic move aims to strengthen supply chain resilience and improve the customer experience. Partnering with a third-party logistics provider, QuidelOrtho aims to fulfill orders more efficiently. The company is also committed to sustainability, introducing greener, paper-based packaging that is recyclable. This initiative is expected to impact 15-20% of its domestic shipments over the coming months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.16%
Tags
none
-
Rhea-AI Summary

QuidelOrtho reported global year-over-year revenue growth of 5% as reported and 6% in constant currency, excluding COVID-19 revenue. They are undergoing cost reduction initiatives to save approximately $100 million annually. The company suspended its 2024 financial guidance as they assess the business under a new President and CEO. Revenue for Q1 2024 was $711 million, with non-respiratory revenue flat at $574 million and respiratory revenue at $137 million, a 48% decrease due to lower COVID-19 revenue. The company appointed Brian J. Blaser as President and CEO effective May 6, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.20%
Tags
-
Rhea-AI Summary

QuidelOrtho (Nasdaq: QDEL) appoints Brian J. Blaser as President and Chief Executive Officer, bringing over two decades of leadership experience in the In-Vitro Diagnostics Industry. The Board of Directors expands to eleven members, with Mr. Blaser joining on May 15, 2024. Known for his success in transformational strategies to drive revenue growth and profitability, Mr. Blaser's appointment is set to guide QuidelOrtho through its next phase of growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.40%
Tags
management
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.95%
Tags
conferences earnings
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
partnership
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.32%
Tags
fda approval covid-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.34%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.03%
Tags
conferences
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.20%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.20%
Tags

FAQ

What is the current stock price of QuidelOrtho (QDEL)?

QuidelOrtho (QDEL) last closed at $8.92.

What is the market cap of QuidelOrtho (QDEL)?

The market cap of QuidelOrtho (QDEL) is approximately $612.0M.